Stockscreener 앱 받기
0.317
5.07%
0.0153
전일 마감가:
$0.3017
열려 있는:
$0.312
하루 거래량:
35,346
Relative Volume:
0.35
시가총액:
$12.62M
수익:
-
순이익/손실:
$-74.56M
주가수익비율:
-0.1731
EPS:
-1.8316
순현금흐름:
$-60.27M
1주 성능:
+4.52%
1개월 성능:
-45.34%
6개월 성능:
-68.61%
1년 성능:
-82.68%
1일 변동 폭
$0.3017
$0.3175
1주일 범위
$0.2895
$0.33
52주 변동 폭
$0.2201
$2.00
Rallybio Corp Stock (RLYB) Company Profile
명칭
Rallybio Corp
전화
203- 859-3820
주소
234 CHURCH STREET, NEW HAVEN
RLYB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.317 | 12.62M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-09 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-17 | 개시 | H.C. Wainwright | Buy |
| 2023-04-10 | 개시 | Wedbush | Outperform |
| 2022-12-09 | 개시 | JP Morgan | Overweight |
| 2022-02-22 | 개시 | JMP Securities | Mkt Outperform |
| 2021-08-23 | 개시 | Cowen | Outperform |
| 2021-08-23 | 개시 | Evercore ISI | Outperform |
| 2021-08-23 | 개시 | Jefferies | Buy |
모두보기
Rallybio Corp 주식(RLYB)의 최신 뉴스
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference - BioSpace
Rallybio Makes Nasdaq Debut - RTTNews
Citizens JMP maintains Rallybio stock at Market Perform By Investing.com - Investing.com Nigeria
Citizens JMP maintains Rallybio stock at Market Perform - Investing.com
Rallybio (NASDAQ:RLYB) Cut to Hold at Evercore ISI - Defense World
Rallybio drops drug for rare maternal disorder following Phase II fail - MSN
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Evercore ISI Downgrades Rallybio to In Line From Outperform - marketscreener.com
Analysts Set Rallybio Co. (NASDAQ:RLYB) Price Target at $9.75 - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns - Investing.com Australia
Rallybio’s (RLYB) Neutral Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Estimates Rallybio’s Q2 Earnings (NASDAQ:RLYB) - Defense World
Evercore ISI cuts Rallybio stock rating on study concerns By Investing.com - Investing.com India
Rallybio (NASDAQ:RLYB) Cut to Hold at Citizens Jmp - Defense World
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks - Yahoo Finance
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Rallybio to Neutral From Buy - MarketScreener
Rallybio sinks as it drops RLYB212 for prevention of FNAIT - The Pharma Letter
Rallybio ends RLYB212 program after trial setback - Investing.com Australia
Citizens JMP cuts Rallybio stock rating following program halt By Investing.com - Investing.com Canada
Rallybio stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Citizens JMP cuts Rallybio stock rating following program halt - Investing.com Australia
Rallybio stock plunges to 52-week low of $0.23 amid market challenges - Investing.com Australia
Rallybio Corporation to Discontinue Development of RLYB212 for Prevention of FNAIT - MarketScreener
Citizens JMP downgrades Rallybio on RLYB212 discontinuation - TipRanks
Rallybio pulls plug on rare pregnancy blood disorder treatment - FirstWord Pharma
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints - Benzinga
Rallybio discontinues lead drug for rare maternal disorder - BioPharma Dive
Rallybio Pivots as Antibody for Rare Bleeding Disorder Flunks Dosing Trial - BioSpace
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
New Haven-based Rallybio discontinues development of rare disease therapy - Hartford Business Journal
Rallybio shares tumble 36% after RLYB212 program halt By Investing.com - Investing.com South Africa
Rallybio shares tumble 36% after RLYB212 program halt - Investing.com India
Rallybio Corp Discontinues Rlyb212 Program For Prevention Of Fnait - marketscreener.com
Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint - Fierce Biotech
Rallybio ends RLYB212 program after trial setback By Investing.com - Investing.com India
Rallybio discontinues RLYB212 program - TipRanks
Major Pipeline Shift: Rallybio Abandons FNAIT Drug to Target Lucrative $6B Disease Market - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday SessionAgilon Health (NYSE:AGL), Alumis (NASDAQ:ALMS) - Benzinga
Rallybio stock plunges to 52-week low, hitting $0.6 - Investing.com Australia
Rallybio stock plunges to 52-week low, hitting $0.6 By Investing.com - Investing.com India
Rallybio stock plunges to 52-week low at $0.62 amid market challenges - Investing.com Canada
Rallybio stock plunges to 52-week low at $0.62 amid market challenges By Investing.com - Investing.com South Africa
Rallybio Corp (RLYB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
2.63%
자본화:
|
볼륨(24시간):